Daniel Kontoh-Boateng | Investor Relations |
Lisa Ricciardi | President and Chief Executive Officer |
John Doyle | Chief Financial Officer |
Tony Caggiano | Chief Medical Officer and Head, R&D |
Charles Duncan | Cantor |
Jay Olson | Oppenheimer |
Aydin Huseynov | Ladenburg |
Good morning, ladies and gentlemen and welcome to Cognition Therapeutics Second Quarter 2023 Earnings Conference Call. My name is Jenny and I will be your conference operator today. This call is being recorded. I would like to turn the presentation over now to your host for today’s call, Daniel Kontoh-Boateng, Investor Relations for Cognition Therapeutics. Please proceed, Mr.